Page 14 of the latest filing. Interesting how the Clone3 will also be used to treat unaffected people as protection
C. Describe the issuers’ principal products or services, and their markets.
The Company’s products consist of two distinct drug development proprietary technologies: Immunotherapy and fully human
monoclonal antibodies.
Enzolytics has proprietary technology for creating human cell lines that produce fully human monoclonal antibodies
against numerous infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and
diphtheria. The Company’s technology for producing fully human monoclonal antibodies is now being employed to
produce anti-SARS-CoV-2 (Coronavirus) monoclonal antibodies for treating COVID-19. The Company plans to employ its
technology to subsequently produce fully human monoclonal antibodies for treating HIV-2, anthrax, smallpox, H1N1
influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus.
The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as
“Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of
all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that
Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98%
(either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by
the Company using Artificial Intelligence (AI).
Using AI, the Company has also identified 8 additional conserved sites on the HIV-1 virus, some with over 98% conserved
sequences, against which the Company plans to produce anti-HIV monoclonal antibodies. Production of multiple
antibodies targeting different conserved and expectedly immutable sites comports with experts’ conclusion that an
effective treatment for HIV and the Coronavirus will likely require the administration of multiple monoclonal additional
antibodies. Effective monoclonal antibodies will be those that target conserved and expectedly immutable virus sites.
Producing targeted antibodies will result in the production of a therapeutic that will not be rendered ineffective due to
mutation (variants) of the virus. In other words, even a “variant form of the virus” will expectedly contain the immutable
targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine
targets a site that nutates.
While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS,
they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from
contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral
therapy for several significant reasons: (1) the therapy will be non-toxic (without damage to the kidneys and liver) and will
not cause bone density deterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require
lifetime treatment and (3) will be far less expensive.
Using its proprietary methodology, the Company is also producing anti-SARS-CoV-2 monoclonal antibodies and has
identified 11 conserved, expectedly immutable epitopes on the Coronavirus against which it plans to produce targeted
monoclonal antibodies. Using AI, the Company has screened the 50,512 Coronavirus isolates currently known and has
identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates
curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512
Coronavirus isolates analyzed by the Company using AI.
Comprehensive patent protection covering these discoveries, relating to HIV and the Coronavirus, have been filed in the
U.S. and will be extended to international coverage under the Patent Cooperation Treaty (PCT). The patent coverage
News 
Market Data 
Discover 
AI
